The subtype lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is classified as triple-negative breast cancer (TNBC), accounting for approximately 20% of BCs. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.